Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals
- Wednesday, July 5, 2023, 7:01
- Finance
- Add a comment
Exclusive license agreement for an oncological target antibody to develop best-in-class ADC LONDON and BEIJING, July 5, 2023 /PRNewswire/ — Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat…
About the Author
adminasapcorp has written 39023 stories on this site.